

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claims 1-18 (cancelled)

Claim 19 (currently amended): A method of treating a patient suffering from a proliferative disease comprising administering an effective amount of a bisphosphonate wherein the bisphosphonate acts to reduce angiogenesis and is selected from the group consisting of 3-amino-1-hydroxypropane-1,1-diphosphonic acid; and 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid; 3-(N,N-dimethylamino)-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxyethidene bisphosphonic acid; 1-hydroxy-3-(methylpentylamino)-propylidene bisphosphonic acid; 6-amino-1-hydroxyhexane-1,1-diphosphonic acid; 3-(N-methyl-N-n-pentylamine)-1-hydroxypropane-1,1-diphosphonic acid; 1-hydroxy-2-(imidazol-1-yl)ethane-1,1-diphosphonic acid; 1-hydroxy-2-(3-pyridyl)ethane-1,1-diphosphonic acid; 1-(4-chlorophenylthio)methane-1,1-diphosphonic acid; 1-hydroxy-3-(pyrrolidin-1-yl)propane-1,1-diphosphonic acid; 1-(N-phenylaminothiocarbonyl)methane-1,1-diphosphonic acid; 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester; 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diphosphonic acid; and 1,1-dichloromethane-1,1-diphosphonic acid and wherein the proliferative disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, breast cancer, colon cancer, small cell lung cancer, prostate cancer, diabetic retinopathy, psoriasis, haemangioblastoma and haemangioma.

Claim 20 (cancelled)

Claims 21-22 (cancelled)